Phase 2 Multicenter Study to Assess the Safety and Efficacy of BKM120 as Monotherapy in Treatment of Initial or Recurrent Metastatic Endometrial Cancer After 1st Line Therapy in Patients Who Cannot Undergo Local Surgery and/or Radiotherapy

Trial Profile

Phase 2 Multicenter Study to Assess the Safety and Efficacy of BKM120 as Monotherapy in Treatment of Initial or Recurrent Metastatic Endometrial Cancer After 1st Line Therapy in Patients Who Cannot Undergo Local Surgery and/or Radiotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Acronyms ENDOPIK
  • Most Recent Events

    • 10 Jan 2017 Results published in the British Journal of Cancer.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 09 Jan 2014 ClinicalTrials.gov record reports change in treatment dose from 100 mg /day to 60 mg/day
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top